{"title":"Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study.","authors":"Chongwen Huang, Wladyslawa Czuber-Dochan, Christine Norton","doi":"10.1097/MEG.0000000000003034","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Depressive symptoms are common in individuals with inflammatory bowel disease (IBD) and are associated with poor disease outcomes. Transcutaneous electrical acupuncture point stimulation (TEAS) is a noninvasive intervention with potential benefits for inflammation but remains untested in IBD. We developed a smartphone application for home-based TEAS self-administration and evaluated its feasibility, acceptability, and preliminary effects.</p><p><strong>Methods: </strong>In a randomized feasibility study, IBD patients with Patient Health Questionnaire-9 (PHQ-9) scores ≥ 8 were recruited through Crohn's and Colitis UK. Participants were remotely trained to use the TEAS device, locate acupoints, and self-administer the treatment via the app. Group A completed 30-min daily sessions for 21 days from week 1, while Group B started in week 6. Outcomes [recruitment, retention, acceptability, depression, fatigue, pain, and quality of life (QoL)] were assessed at baseline, week 4, and week 9.</p><p><strong>Results: </strong>Of the 109 individuals of interest, 57 were assessed, 37 were eligible, and 36 were randomized. In Group A, 83% (15/18) completed ≥ 18 sessions, compared to 50% (9/18) in Group B. The questionnaire completion rates were 92% ( n = 33) at baseline, 83% ( n = 30) at 4 weeks, and 67% ( n = 24) at 9 weeks. Most participants (81%) recommended TEAS. Preliminary analysis showed reduced depressive symptoms and improved QoL postintervention and at the follow-up. Postintervention, the mean PHQ-9 score decreased from 13.9 to 7.7 in Group A and from 14.2 to 6.5 in Group B.</p><p><strong>Conclusions: </strong>Home-based TEAS is feasible, acceptable, and has a clinical potential. A full-scale randomized controlled trial is needed to confirm its efficacy in the treatment of IBD-related depression.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000003034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Depressive symptoms are common in individuals with inflammatory bowel disease (IBD) and are associated with poor disease outcomes. Transcutaneous electrical acupuncture point stimulation (TEAS) is a noninvasive intervention with potential benefits for inflammation but remains untested in IBD. We developed a smartphone application for home-based TEAS self-administration and evaluated its feasibility, acceptability, and preliminary effects.
Methods: In a randomized feasibility study, IBD patients with Patient Health Questionnaire-9 (PHQ-9) scores ≥ 8 were recruited through Crohn's and Colitis UK. Participants were remotely trained to use the TEAS device, locate acupoints, and self-administer the treatment via the app. Group A completed 30-min daily sessions for 21 days from week 1, while Group B started in week 6. Outcomes [recruitment, retention, acceptability, depression, fatigue, pain, and quality of life (QoL)] were assessed at baseline, week 4, and week 9.
Results: Of the 109 individuals of interest, 57 were assessed, 37 were eligible, and 36 were randomized. In Group A, 83% (15/18) completed ≥ 18 sessions, compared to 50% (9/18) in Group B. The questionnaire completion rates were 92% ( n = 33) at baseline, 83% ( n = 30) at 4 weeks, and 67% ( n = 24) at 9 weeks. Most participants (81%) recommended TEAS. Preliminary analysis showed reduced depressive symptoms and improved QoL postintervention and at the follow-up. Postintervention, the mean PHQ-9 score decreased from 13.9 to 7.7 in Group A and from 14.2 to 6.5 in Group B.
Conclusions: Home-based TEAS is feasible, acceptable, and has a clinical potential. A full-scale randomized controlled trial is needed to confirm its efficacy in the treatment of IBD-related depression.
期刊介绍:
European Journal of Gastroenterology & Hepatology publishes papers reporting original clinical and scientific research which are of a high standard and which contribute to the advancement of knowledge in the field of gastroenterology and hepatology.
The journal publishes three types of manuscript: in-depth reviews (by invitation only), full papers and case reports. Manuscripts submitted to the journal will be accepted on the understanding that the author has not previously submitted the paper to another journal or had the material published elsewhere. Authors are asked to disclose any affiliations, including financial, consultant, or institutional associations, that might lead to bias or a conflict of interest.